We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Industry-First Custom AI Technology Revolutionizes End-to-End Breast Diagnostics

By MedImaging International staff writers
Posted on 26 Jan 2024
Print article
Image: The groundbreaking DANAI technology has received the CE mark (Photo courtesy of b-rayZ)
Image: The groundbreaking DANAI technology has received the CE mark (Photo courtesy of b-rayZ)

Accurate diagnosis is critical for effective breast imaging. Now, an AI-powered diagnostic system enhances the expertise of radiologists by delivering intelligent insights and highlighting possible concern areas, thereby improving diagnostic accuracy. This can lead to earlier detection, lower false positives, and ultimately, improved patient outcomes.

b-rayZ, based in Zurich, Switzerland, is revolutionizing breast cancer diagnostics with its cutting-edge DANAI technology. This innovation is a core part of b-rayZ's comprehensive breast diagnostic suite, b-box plus, which significantly enhances breast cancer detection, and density assessment, and ensures quality in breast positioning. DANAI represents a groundbreaking shift in radiology, introducing a Custom AI framework uniquely tailored to meet the specific needs of breast imaging institutions and their professional teams. This shift in AI technology emphasizes adaptability, enabling it to be seamlessly integrated into a variety of clinical settings. The flexible framework of DANAI is designed to calibrate according to the unique requirements of each imaging unit, thus improving diagnostic accuracy and operational efficiency.

b-rayZ's AI solution forms part of a growing multi-modality platform devoted exclusively to breast cancer diagnostics. The company supports women on their diagnostic journey by offering a tailored ecosystem of solutions that address clinical needs. Combining advanced AI technology with extensive clinical experience in breast imaging, b-rayZ delivers a comprehensive and user-friendly solution. It encompasses a range of industry-leading AI modules, each crafted to meet the specific requirements of healthcare professionals, including medical radiology assistants, radiologists, and hospital managers. DANAI, the latest innovation from b-rayZ, is poised to redefine AI capabilities in medical diagnostics, offering a custom AI framework that excels in adaptability, safety, precision, and efficiency. Set for imminent launch, DANAI technology is expected to significantly advance the field of medical imaging, establishing new benchmarks in excellence and innovation. Additionally, b-rayZ has attained CE mark certification for its pioneering DANAI technology.

"The CE mark for DANAI is a tribute to our commitment to innovation and excellence in breast imaging,” said Prof. Dr. Cristina Rossi, CEO of b-rayZ. “With this achievement, b-rayZ elevates itself in the medical industry as the first company to cover the entire mammography workflow, closing the last gap in the adoption of AI in each and every setting with Custom AI capabilities. This innovation revolutionizes the diagnostic landscape through our commitment to the highest quality breast cancer diagnostics."

 

X-ray Diagnostic System
FDX Visionary-A
Portable X-ray Unit
AJEX140H
New
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Multi-Use Ultrasound Table
Clinton

Print article

Channels

MRI

view channel
Image: An AI tool has shown tremendous promise for predicting relapse of pediatric brain cancer (Photo courtesy of 123RF)

AI Tool Predicts Relapse of Pediatric Brain Cancer from Brain MRI Scans

Many pediatric gliomas are treatable with surgery alone, but relapses can be catastrophic. Predicting which patients are at risk for recurrence remains challenging, leading to frequent follow-ups with... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.